Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 13/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29826525 | 0.84 | GLP1R (0.46) | GLP1R | |
| SCHEMBL29103539 | 0.84 | GLP1R (0.46) | GLP1R | |
| SCHEMBL29103543 | 0.84 | GLP1R (0.46) | GLP1R | |
| SCHEMBL20266496 | 0.84 | GLP1R (0.50) | GLP1R | |
| SCHEMBL22009843 | 0.83 | GLP1R (0.51) | GLP1RGRM2KMT2AACSS2 | |
| SCHEMBL30676073 | 0.83 | GLP1R (0.51) | GLP1RGRM2KMT2AACSS2 | |
| SCHEMBL29826194 | 0.82 | GLP1R (0.47) | GLP1RKMT2AACSS2 | |
| SCHEMBL30740742 | 0.82 | GLP1R (0.47) | GLP1RKMT2AACSS2 | |
| SCHEMBL22009923 | 0.79 | GLP1R (0.48) | GLP1RACSS2 | |
| SCHEMBL28697136 | 0.79 | GLP1R (0.41) | GLP1RKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3972596-B1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4219487-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119462621-A | GLP-1 receptor agonists and uses thereof | 辉瑞公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119462622-A | GLP-1 receptor agonists and uses thereof | 辉瑞公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119431342-A | GLP-1 receptor agonists and uses thereof | 辉瑞公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-3972596-A1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | Pfizer Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20210332034-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2021-10-28 | — | — | US | disclosed |
| US-20210163455-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163455-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10934279-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934279-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331041-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885GRM2 521/4885KMT2A 1805/4885 |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885GRM2 521/4885KMT2A 1805/4885 |
| US-20210163455-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885GRM2 521/4885KMT2A 1805/4885 |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885GRM2 521/4885KMT2A 1805/4885 |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885GRM2 521/4885KMT2A 1805/4885 |
| US-20210332034-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885GRM2 521/4885KMT2A 1805/4885 |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885GRM2 521/4885KMT2A 1805/4885 |
| US-20250270196-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885GRM2 521/4885KMT2A 1805/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | GLP1R 1/4885GRM2 261/4885KMT2A 481/4885 |
| US-10934279-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | GLP1R 1/4885GRM2 521/4885KMT2A 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.